Affymetrix, Inc. (NASDAQ:AFFX) today launched its Anatrace® brand Neopentyl Glycol (NG) Class™ Detergents, the next generation of detergents to significantly advance the study of integral membrane proteins (IMPs), the most important proteins found in the human genome. Developed by leading chemists, and available only from Affymetrix, ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), presented positive safety data in its ongoing LibiGel Phase III clinical development program, at the annual meeting of ISSWSH on February 12, 2011. BioSante reported that with 2,869 women enrolled and over 3,000 women-years ... read more

Napo Pharmaceuticals, Inc. (Napo) is pleased to announce the positive results of a successfully completed Phase 2 study of crofelemer for the treatment of hospitalized adult patients with mild to moderate acute watery diarrhea conducted by its partner Glenmark Pharmaceuticals Ltd. (Glenmark - BSE: 532296 NSE: ... read more

The Therapeutic Discovery Project (TDP) is important to the viability of the companies receiving a TDP award and allowed these small businesses to create or sustain jobs, according to a new survey of CEOs of small biotech firms that received Therapeutic Discovery Project awards last fall. ... read more

The Biotechnology Industry Organization (BIO) today announced that President and CEO James C. Greenwood will ring the closing bell at The NASDAQ Stock Market on February 15, 2011 together with numerous executives representing the life science industry. This ceremony concludes the 13th ... read more

Bruker Corporation (NASDAQ: BRKR) announced today that it plans to release its fourth quarter and fiscal year 2010 financial results on Wednesday, February 23rd, 2011 before the market opens. Bruker will then host an operator-assisted earnings conference call that morning at 9:00 AM Eastern Time. To ... read more

Research and Markets (http://www.researchandmarkets.com/research/cc76c2/analytical_tool) has announced the addition of the "Analytical Tool - Hematological Cancers" report to their offering. "Analytical Tool Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged ... read more

Efficiency records, plenty of new funding, expansion announcements – as solar thin-film technology based on copper, indium, gallium and selenium/sulphur (CIS/CIGS) is reaching unseen momentum, premier photovoltaics publisher PHOTON has dedicated its 3rd Thin Film Conference: CIS – High efficiency and low cost? to this ... read more

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that its Co-Founder/Chief Scientific Advisor, Eric N. Olson, Ph.D., and scientific Co-Founder/Director of Biology, Eva van ... read more

Feb. 11, 2011--Senomyx, Inc. (NASDAQ: SNMX) will release its financial results for the fourth quarter and fiscal year ended December 31, 2010 on Thursday, March 3, 2011 before the opening of the U.S. financial markets. The Company will also host a conference call with a live ... read more

Inhibitex, Inc. (Nasdaq: INHX) today reported that the U.S. Food and Drug Administration (“FDA”) has designated the investigation of INX-08189 (“INX-189”), a potent guanosine nucleotide polymerase inhibitor for the treatment of chronic hepatitis C viral infection, as a Fast Track development program. Under the FDA Modernization ... read more

RAPID 2011, a conference and exposition showcasing how additive manufacturing is used to create almost any solid product while reducing production costs, will be held in Minneapolis, May 24–26, 2011. Nowhere else in North America will professionals find such ... read more

Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it expects to report revenue for the fourth quarter of 2010 of $51.8 million, an increase of 7% compared to $48.3 ... read more

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the fourth quarter and year ended December 31, 2010. Targacept reported a net loss of $2.2 million for the fourth quarter ... read more

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 first quarter ended December 31, 2010. “With the sale of Unidym last month, Arrowhead ... read more

MannKind Corporation (Nasdaq:MNKD) today reported financial results for the fourth quarter and year ended December 31, 2010. For the fourth quarter of 2010, total operating expenses were $32.1 million, compared to $55.8 million for the fourth quarter of 2009, a ... read more

The race to develop a commercially viable hydrogen fuel cell just got a boost from a $1.9 million state award to a high-tech company that is planning to turn breakthrough nanotechnology pioneered at Florida State University into a better, faster, more economical fuel cell. In a ... read more

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the publication of the full results of the AVERROES study of apixaban in The New England Journal of Medicine. Conducted in 36 countries, the study was coordinated by ... read more

Instem, a leading provider of early development software applications, announced today that SNBL USA has placed an order for 500 users of its Provantis® preclinical software solution suite. SNBL USA will be using the integrated Provantis solution suite to offer their biotechnology and pharmaceutical clients’ unparalleled ... read more

Imaging Diagnostic Systems, Inc., (OTCBB:IMDS.OB), a pioneer in laser breast imaging, announced today that it has completed installation and training for its (CTLM®) in Jakarta, Indonesia at the Hang Lekiu Medical Center. Hang Lekiu Medical Center provides multi-disciplined medical ... read more